111 related articles for article (PubMed ID: 23116353)
1. [A new opportunity in ovarian cancer treatment].
Sedláková I
Ceska Gynekol; 2012 Oct; 77(5):469-71. PubMed ID: 23116353
[TBL] [Abstract][Full Text] [Related]
2. [Chemoresistance/Chemosensitivity of ovarian cancer--a case report].
Sedláková I; Tosner J; Rezác A; Cervinka M; Tomsová M; Spacek J
Ceska Gynekol; 2008 Jun; 73(3):140-3. PubMed ID: 18646664
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab in the treatment of ovarian cancer.
Heitz F; Harter P; Barinoff J; Beutel B; Kannisto P; Grabowski JP; Heitz J; Kurzeder C; du Bois A
Adv Ther; 2012 Sep; 29(9):723-35. PubMed ID: 22941523
[TBL] [Abstract][Full Text] [Related]
4. [Vascular endothelial growth factor in ovarian cancer patients].
Sedláková I; Tošner J; Kopecký O; Vroblová V; Rezáč A; Skapinec P; Andrýs C
Ceska Gynekol; 2012 Oct; 77(5):415-20. PubMed ID: 23116346
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab in ovarian cancer.
Mountzios G; Pentheroudakis G
N Engl J Med; 2012 Mar; 366(13):1257; author reply 1258. PubMed ID: 22455430
[No Abstract] [Full Text] [Related]
6. Bevacizumab in ovarian cancer.
Copur MS; Obermiller AM; Ramaekers R
N Engl J Med; 2012 Mar; 366(13):1256-7; author reply 1257-8. PubMed ID: 22455429
[No Abstract] [Full Text] [Related]
7. Bevacizumab in ovarian cancer.
Korn EL; Freidlin B; Abrams JS
N Engl J Med; 2012 Mar; 366(13):1256; author reply 1257-8. PubMed ID: 22455428
[No Abstract] [Full Text] [Related]
8. Gynecological cancer: First-line bevacizumab for ovarian cancer--new standard of care?
Banerjee S; Kaye SB
Nat Rev Clin Oncol; 2012 Feb; 9(4):194-6. PubMed ID: 22371131
[No Abstract] [Full Text] [Related]
9. [Resistance/sensitivity in vitro in ovarian cancer patients].
Sedláková I; Tosner J; Rezác A; Cervinka M; Brigulová K; Spacek J; Tomsová M; Skapinec P
Ceska Gynekol; 2010 May; 75(3):182-7. PubMed ID: 20731297
[TBL] [Abstract][Full Text] [Related]
10. [Histopathologic prognostic factors, serum markers and selected molecular biologic factors in ovarian carcinoma].
Spacek J; Jílek P; Petera J; Tesarík Z
Ceska Gynekol; 2002 Nov; 67(6):343-9. PubMed ID: 12661373
[TBL] [Abstract][Full Text] [Related]
11. Personalized ovarian cancer treatment.
Rodriguez AO
Curr Opin Obstet Gynecol; 2012 Feb; 24(1):1-2. PubMed ID: 22193244
[No Abstract] [Full Text] [Related]
12. Beyond bevacizumab: investigating new angiogenesis inhibitors in ovarian cancer.
Tomao F; Papa A; Rossi L; Caruso D; Zoratto F; Benedetti Panici P; Tomao S
Expert Opin Investig Drugs; 2014 Jan; 23(1):37-53. PubMed ID: 24111925
[TBL] [Abstract][Full Text] [Related]
13. [Treatment strategies in ovarian cancer].
Puistola U; Leminen A
Duodecim; 2013; 129(18):1917-24. PubMed ID: 24187783
[TBL] [Abstract][Full Text] [Related]
14. The role of bevacizumab in recurrent, platinum-sensitive ovarian cancer.
Gubbi A; Kendrick JE; Finkler NJ
Expert Rev Anticancer Ther; 2014 Oct; 14(10):1105-13. PubMed ID: 25189201
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab for the treatment of epithelial ovarian cancer: will this be its finest hour?
Kaye SB
J Clin Oncol; 2007 Nov; 25(33):5150-2. PubMed ID: 18024860
[No Abstract] [Full Text] [Related]
16. [Primary drug resistance/sensitivity in vitro and clininical outcome in ovarian cancer patients].
Sedláková I; Tosner J; Cervinka M; Brigulová K; Rezác A; Spacek J; Laco J; Skapinec P
Ceska Gynekol; 2011 Jun; 76(3):184-9. PubMed ID: 21838147
[TBL] [Abstract][Full Text] [Related]
17. [Vulvodynia and the possibility of its management].
Kestránek J; Matula V; Pidrman V; Taláb R; Jílek P; Buchta V; Spacek J
Ceska Gynekol; 2010 Dec; 75(6):521-6. PubMed ID: 27534008
[TBL] [Abstract][Full Text] [Related]
18. [Para-aortic lymphadenectomy in gynecology. Theoretical principles, basic approach and practical suggestions].
Spacek J; Veselský Z; Tosner J; Tesarík Z
Ceska Gynekol; 2003 Mar; 68(2):99-105. PubMed ID: 12749178
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab in the treatment of ovarian cancer: a meta-analysis from four phase III randomized controlled trials.
Ye Q; Chen HL
Arch Gynecol Obstet; 2013 Sep; 288(3):655-66. PubMed ID: 23543268
[TBL] [Abstract][Full Text] [Related]
20. How to approach patients in relapse.
Pujade-Lauraine E
Ann Oncol; 2012 Sep; 23 Suppl 10():x128-31. PubMed ID: 22987947
[No Abstract] [Full Text] [Related]
[Next] [New Search]
